SynAct Pharma AB (“SynAct”) today announced additional results on the secondary endpoints ACR50 and ACR70 from the Phase 2a study of AP1189 (BEGIN) in early rheumatoid arthritis (RA) patients experiencing severe disease activity.
This update includes evaluation of the treatment effects by ACR scoring, named after the American College of Rheumatology. In addition to the ACR20 scores (proportion of the patients that achieved a reduction of ACR score ≥ 20%), the company has analyzed the treatment effects using the ACR50 and ACR70 scores.
For ACR50 (≥50% improvement in the ACR score) the results for placebo, 50 mg AP1189 and 100 mg AP1189 were 6.7%, 3.5%, and 18.2%, respectively.
For ACR70 (≥70% improvement in the ACR score) the results were 3.3%, 0% and 9.1% for placebo, 50 mg AP1189 and AP1189 100 mg, respectively.
An updated presentation with the results from the BEGIN study, including the information above is available on the company’s web site: www.synactpharma.com
SynAct continues to analyze the data set from BEGIN and additional results will be announced during the coming months.
The information was submitted, through the agency of the contact person below, for publication on December 2, 2021.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69
Mail: [email protected]